ICAM1 and rheumatoid arthritis: This includes the discontinuation of phase II clinical trials studying MMP inhibitors in RA (Thabet and Huizinga, 2006; Dorman et al., 2010), as well as reduced efficacy of repeated administration of anti-ICAM-1 mAb in RA patients (Kavanaugh et al., 1996, 1997).